my class work on pharmaceutical export

1. B Y : H E M A N T C H A N D W A N I
M B A ( P H A R M A C E U T I C A L M A N A G E M E N T ) - 0 7
Pharmaceutical Exports
(Pharmexcil)

2. INTRODUCTION
 India is one of the fastest-growing pharmaceutical
markets in the world and has established itself as a
global manufacturing and research hub.
 A large raw material base and the availability of a
skilled workforce give the industry a definite
competitive advantage.

3. Pharmaceutical Export Promotion
Council
 Pharmaceutical Export Promotion Council of
India (Pharmexcil) is the authorized agency of the
government of India.
 It was set up under the provisions of Foreign Trade
Policy by the Ministry of Commerce and Industry in
May 2004.
 Pharmexcil takes up several external trade
promotion activities by organizing trade delegations
outside India, arranging buyer-seller meetings,
international seminars, etc.

4. Cont....
 The agency's headquarters is located in Hyderabad.
 Executive Director Dr. P V Appaji and Shri D.B.
Mody is the founding Chairman.
 The present Chairman Shri Ashutosh Gupta,
Medicamen Biotech Ltd

5. Highlights
 The Indian pharmaceutical industry was estimated to be
worth US$ 12 billion in 2013 and is expected to touch
US$ 100 billion by 2025.
 Globally, India ranks third in terms of volume of
production and fourteenth largest by value and is also
expected to move up to eleventh place by 2017.
 Indian pharma sales stood at US$ 22.6 billion in 2012
and is expected to register US$ 27 billion by 2016
growing at a rate of 14.4 percent.
 The domestic pharma sector is witnessing strong growth
due to higher penetration in tier-II and tier-III cities and
greater focus on the largely-untapped rural market.

6. Key Markets and Exports
 India exports to more than 200 countries; its share of
exports is expected to grow manifold.
 Pharmaceutical exports from India grew at a rate of 1.2
per cent to reach US$ 14.84 billion in 2013-14.
 The US is the prime importer of pharmaceuticals from
India and accounts for nearly 25 per cent of Indian
pharmaceutical exports, followed by the European Union
and Africa at second and third positions respectively.
 The export of bulk drugs continue to grow to regulated
markets and is supported by India’s existing foothold in
semi-regulated market.

7. Pharmaceutical Exports of India
 Drugs, Pharmaceuticals and Fine Chemicals have
been Fifth largest exported principal commodity of
the country.
 accounting for 4.8% of India's Total Exports.
 In line with last two decades India's Pharmaceutical
Industry.
 it has achieved a positive trade balance and the
initial estimates puts it around USD 9.0to 10.0
billion.

8. Cont...
 As per the latest periodic statistics released by Director
General of Commercial Intelligence & Statistics (DGCIS).
 Pharmaceuticals for the period April 2013 to March 2014
stood at USD 15,045 million recording a growth rate
2.5% over the corresponding period of previous year.
 During 2013-14 India’s Exports of Finished Dosage forms
is 74%
 The total exports Bulk Drugs in the region of 24% and
Herbals 2%. Finished Dosage forms contribution is on
the increase
 Indicates increased recognition of India’s
Pharmaceuticals World over.

10. Pharmaceutical Exports of India
 The Top 25 destinations of India's Pharmaceutical
Exports.
 USA remains the top export destination with a share
of 26.73 %.
 Amounting to $ 4022 million growth of 7.9%.
 Among the top 25 destination countries, exports to
Ethiopia, Uganda,& Tanzania, have grown
exceptionally in comparison to the average growth.

11. India In global arena
 To-day India’s Pharmaceutical Industry is known
“Global pharmacy of the world”.
 India offers almost every product which has gone off
patent and with a large vendor base.
 India’s filings of DMF’s with USFDA as of Dec 2013
is 3411, the highest filed by any country in the world.
 The below table gives complete tally of accreditations
India’s exporters have received from various
countries regulating authorities.

13. India In global arena
 India after
achieving
considerable
success in first to
file ANDAs with
USFDA, has now
made a beginning
in the segment of
super generics.

14. References
 www. pharmexcil .com
 www.nber.org/papers/w87
 indiainbusiness.nic.in/newdesign/index.php?para
m=industryservices.
 www. india- opportunities.es/
pharmaceuticalindustry.php?lang=ing